<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04190615</url>
  </required_header>
  <id_info>
    <org_study_id>NICDOS1TEMCP</org_study_id>
    <nct_id>NCT04190615</nct_id>
  </id_info>
  <brief_title>Determination of ClotPro Paediatric Reference Range Study</brief_title>
  <official_title>Determination of Reference Ranges of Thromboelastometry ClotPro Analyser in Paediatric Patients Undergoing Elective Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Children's Diseases, Slovakia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Children's Diseases, Slovakia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A new thromboelastometry analyser (ClotPro, Enicor GmbH, Munich, Germany) with improved&#xD;
      technology was developed. This device has an improved new-generation viscoelastometric&#xD;
      testing technique and enables the detection and assessment of factor deficiencies, low&#xD;
      fibrinogen, platelet contribution (to whole blood coagulation), heparin and direct oral&#xD;
      anticoagulants effects, fibrinolysis and antifibrinolytic drugs. This study aims to determine&#xD;
      reference ranges for the ClotPro device for all paediatric age groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Viscoelastic testing as a relatively novel method to assess coagulation status appears&#xD;
      favourable in reducing blood product transfusions. The tests are performed on whole blood&#xD;
      instead of plasma, which saves time and gives a quick sight at the interaction between&#xD;
      cellular and plasmatic clotting factors.&#xD;
&#xD;
      Reviews of the literature suggest that transfusions of packed red blood cells (pRBC), plasma,&#xD;
      and platelets are all decreased in patients whose transfusions were guided by viscoelastic&#xD;
      tests rather than by clinical judgement or conventional laboratory tests.&#xD;
&#xD;
      The benefits of viscoelastic coagulation monitoring have been described in many fields of&#xD;
      surgery and intensive care. Current literature and a guideline for the treatment of massive&#xD;
      haemorrhage in perioperative bleeding and trauma patients recommend the use of viscoelastic&#xD;
      tests to guide haemostatic resuscitation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 17, 2019</start_date>
  <completion_date type="Actual">January 5, 2021</completion_date>
  <primary_completion_date type="Actual">January 5, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>reference range for the thromboelastometry analyser (ClotPro, Enicor GmbH, Munich, Germany) in age group 0 to 3 months for EX-test, FIB-test, IN-test, HI-test, RVV test and TPA test</measure>
    <time_frame>30 minutes post blood sampling</time_frame>
    <description>Measurement of thromboelastometry parameters in paediatric patients of 0-3months age group undergoing elective surgery or diagnostic procedure requiring general anaesthesia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>reference range for the thromboelastometry analyser (ClotPro, Enicor GmbH, Munich, Germany) in age group 4 to 12 months for EX-test, FIB-test, IN-test, HI-test, RVV test and TPA test .</measure>
    <time_frame>30 minutes post blood sampling</time_frame>
    <description>Measurement of thromboelastometry parameters in paediatric patients of 4-12months age group undergoing elective surgery or diagnostic procedure requiring general anaesthesia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>reference range for the thromboelastometry analyser (ClotPro, Enicor GmbH, Munich, Germany) in age group 13 to 24 months for EX-test, FIB-test, IN-test, HI-test, RVV test and TPA test .</measure>
    <time_frame>30 minutes post blood sampling</time_frame>
    <description>Measurement of thromboelastometry parameters in paediatric patients of 13-24months age group undergoing elective surgery or diagnostic procedure requiring general anaesthesia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>reference range for the thromboelastometry analyser (ClotPro, Enicor GmbH, Munich, Germany) in age group 2 to 5 years for EX-test, FIB-test, IN-test, HI-test, RVV test and TPA test</measure>
    <time_frame>30 minutes post blood sampling</time_frame>
    <description>Measurement of thromboelastometry parameters in paediatric patients of 2-5years age group undergoing elective surgery or diagnostic procedure requiring general anaesthesia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>reference range for the thromboelastometry analyser (ClotPro, Enicor GmbH, Munich, Germany) in age group 6 to10 years for EX-test, FIB-test, IN-test, HI-test, RVV test and TPA test</measure>
    <time_frame>30 minutes post blood sampling</time_frame>
    <description>Measurement of thromboelastometry parameters in paediatric patients of 6 to10 years group undergoing elective surgery or diagnostic procedure requiring general anaesthesia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>reference range for the thromboelastometry analyser (ClotPro, Enicor GmbH, Munich, Germany) in age group 11-16 years for EX-test, FIB-test, IN-test, HI-test, RVV test and TPA test</measure>
    <time_frame>30 minutes post blood sampling</time_frame>
    <description>Measurement of thromboelastometry parameters in paediatric patients of 11-16 years group undergoing elective surgery or diagnostic procedure requiring general anaesthesia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Age related differences in thromboelastometry parameters</measure>
    <time_frame>12 months</time_frame>
    <description>possible differences in monitored parameters across age groups;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gender-related differences in thromboelastometry parameters</measure>
    <time_frame>12 months</time_frame>
    <description>possible differences in parameters between genders.</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Actual">322</enrollment>
  <condition>Clotting and Bleeding Disorders</condition>
  <condition>Child Development</condition>
  <condition>Infant Development</condition>
  <condition>Coagulopathy</condition>
  <arm_group>
    <arm_group_label>0 to 3 months</arm_group_label>
    <description>0 (term newborns) to 3 month of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 to12 months</arm_group_label>
    <description>infants from 4month to 12month of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>13 to 24 months</arm_group_label>
    <description>children from 13month to 2years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 to 5 years</arm_group_label>
    <description>children from 2 to 5 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 to 10 years</arm_group_label>
    <description>children from 2 to 10 years of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>11 to16 years</arm_group_label>
    <description>children from 11 to 16 years of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>thromboelastometry test (TEM test)</intervention_name>
    <description>TEM test from the whole blood sample</description>
    <arm_group_label>0 to 3 months</arm_group_label>
    <arm_group_label>11 to16 years</arm_group_label>
    <arm_group_label>13 to 24 months</arm_group_label>
    <arm_group_label>2 to 5 years</arm_group_label>
    <arm_group_label>4 to12 months</arm_group_label>
    <arm_group_label>6 to 10 years</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        6 Individual age categories are determined to monitor: ASA physical status I-II&#xD;
&#xD;
          1. 0 (full term) to 3 months&#xD;
&#xD;
          2. 4 to12 months&#xD;
&#xD;
          3. 13 to 24 months&#xD;
&#xD;
          4. 2 to 5 years&#xD;
&#xD;
          5. 6 to10 years&#xD;
&#xD;
          6. 11 to 16 years Demographic data to be recorded: age, gender, weight, height.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  paediatric patients attending hospital for elective surgery or diagnostic imaging&#xD;
             undergoing general anaesthesia are going to be eligible to participate.&#xD;
&#xD;
          -  children whose parents agree to participate are provided with oral and written&#xD;
             information and written informed consent has to be obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  problematic blood collection&#xD;
&#xD;
          -  age over 16 years&#xD;
&#xD;
          -  emergency surgery&#xD;
&#xD;
          -  systemic infection&#xD;
&#xD;
          -  known bleeding disorders&#xD;
&#xD;
          -  history of congenital or acquired coagulopathy including renal, liver and bone marrow&#xD;
             disease,&#xD;
&#xD;
          -  any medication interfering with haemostasis&#xD;
&#xD;
          -  prophylactic or therapeutic anticoagulant therapy (acetylsalicylic acid within the&#xD;
             last 10 days or low-molecular-weight heparins within the last 48 h)&#xD;
&#xD;
          -  administration of colloids hydroxyethyl starch (HES)/albumin, or blood products before&#xD;
             the blood withdrawal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katarina Laukova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Children's Diseases, Bratislava</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute of Children's Diseases, Bratislava</name>
      <address>
        <city>Bratislava</city>
        <zip>833 40</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 30, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Children's Diseases, Slovakia</investigator_affiliation>
    <investigator_full_name>Katarina Laukova, MD</investigator_full_name>
    <investigator_title>Paediatric Anaesthetist, Attending physician</investigator_title>
  </responsible_party>
  <keyword>thromboelastometry</keyword>
  <keyword>viscoelastic testing</keyword>
  <keyword>reference ranges</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

